A simple, objective blood test for predicting preeclampsia risk.
A breakthrough for predicting risk months before it strikes. Prevention is possible.
Encompass test identified 9 out of 10 eligible pregnancies that developed preeclampsia between 20 and 37 weeks, months early. Eligible pregnancies are singleton, age 35 or older, and without a pre-existing major risk factor for preeclampsia.1 Clinical performance data is available upon request. The test is powered by the Mirvie RNA platform, which analyzes tens of thousands of RNA messages from the baby, placenta, and the mom. The patented platform is a new, more effective way to predict pregnancy complications.
Simple blood test
A simple maternal blood draw is conducted between 18 and 22 weeks of pregnancy.
Cutting-edge RNA analysis
Our CLIA lab analyzes the sample to decode patterns in RNA activity to reveal if a pregnancy is at high or low risk for preeclampsia.
Objective results & action plan
Your patients' risk level and personalized action plan is delivered within 2 weeks. Together, you can take proactive measures that fit their unique pregnancy that will result in better outcomes for mom and baby.
- Low-risk result
- High-risk result
Understanding low-risk results
Low-risk results indicate there is a decreased risk of developing preeclampsia in this pregnancy.
Still, there are many things your patient can do to lower their risk for preeclampsia even more.
Each test report includes a customized plan that will provide options for you and them to do everything possible to prevent preeclampsia and recognize it right away if it does occur.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Reported health history
Each test report provides a summary of the individual's health history, focusing on major risk factors for preeclampsia.
It is essential to interpret test results while considering other clinical factors and evaluation for additional pregnancy complications should align with guideline recommendations.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Customized care plans
Each test report features a personalized care plan and recommendations tailored to the patient's test results, including a summary and a list of in-depth actions for each evidence-based prevention strategy.
These recommendations can significantly differ depending on whether the result indicates low or high risk.
Explore these evidence-based strategies further in:
"Care Plan for Individuals at Risk of Preeclampsia: a Collaborative Approach to Education, Prevention Strategies, Surveillance, and Follow-Up" by J. Roberts et al. (AJOG 2023).
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Risks and warning signs
Whether your patient is at low or high risk, it is crucial that they comprehend the potential dangers of preeclampsia.
Both you and the patient need to stay alert for any signs and symptoms and promptly identify them if they do arise. This proactive approach enables swift action for the best possible care for both the mother and the baby.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
More information
In a clinical validation study, Encompass identified 9 out of 10 eligible pregnancies that developed preeclampsia between 20 and 37 weeks, months in advance. Note: clinical performance data is available upon request.
The performance characteristics of the Encompass test have been established in pregnant individuals age 35 or older and without a pre-existing major risk factor for preeclampsia, with a singleton pregnancy between 17 weeks 4 days and 22 weeks 0 days gestation.
Given this test is intended for screening preeclampsia risk, a "high-risk" result does not guarantee an affected pregnancy, and a "low-risk" result does not guarantee an unaffected pregnancy.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Patient name: Jane Doe
Encompass result:
Low Risk
There is a decreased risk of developing
preeclampsia in this pregnancy.
With a "low-risk" result, Encompass Care is recommended for your pregnancy. Although your risk of preeclampsia is low, there are still steps you can take to help have a healthy pregnancy. Discuss your recommended care plan with your provider.
Patient name: Jane Doe
Medical history and risks
Jane, you also reported no major risk factors for preeclampsia in your history. This is reassuring, but there are still steps you can take to lower your risk for preeclampsia even more in your recommended care plan.
Patient name: Jane Doe
Your suggested care plan
Review the specific recommendations outlined in your "low-risk" care plan with your provider to determine the best plan for your pregnancy. This is a brief summary:
- Medications: Based on your results, you don't require any medications. However, some providers may still suggest you take baby aspirin.
- Monitoring and labs: It's important to know the signs and symptoms of preeclampsia and get your blood pressure checked regularly.
- Nutrition: The Mediterranean diet can lower preeclampsia risk. Vitamin D and calcium are also important.
- Exercise: Exercise can lower your preeclampsia risk significantly.
- Sleep: While it may seem simple, it can make a difference.
Patient name: Jane Doe
Understanding your risk
Preeclampsia can cause serious complications for both moms and babies. Even with a "low-risk" result, a small percentage of people will still develop preeclampsia, and there are certain symptoms you should to be aware of.
When there are symptoms, they may include:
- Headache that will not go away
- Shortness of breath
- Pain in the abdomen or shoulder
- Nausea or vomiting in the second half of pregnancy
- Seeing spots, blurry vision, changes in eyesight
- Swelling of face or hands
- Sudden weight gain
- High blood pressure
Patient name: Jane Doe
About the test
Encompass is a screening test, not a diagnostic. It evaluates gene expression levels in the maternal blood, which is a mixture of maternal, fetal and placental origin, to predict the chance for preeclampsia.
The test isolates RNA from the maternal blood, from which libraries are created and analyzed by next generation sequencing and analyzed using Mirvie’s proprietary bioinformatics pipeline.
Note: this is a mock test report. Clinical performance data is available upon request.
Understing high-risk results
High-risk results indicate there is an increased risk of developing preeclampsia in this pregnancy.
It is critical you and your patient work together to implement a care plan based on evidence-based strategies for preventing preeclampsia.
Each test report includes a customized plan that will provide options for you and them to do everything possible to prevent preeclampsia and recognize it right away if it does occur.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Reported health history
Each test report provides a summary of the individual's health history, focusing on major risk factors for preeclampsia.
It is essential to interpret test results while considering other clinical factors and evaluation for additional pregnancy complications should align with guideline recommendations.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Customized care plans
Each test report features a personalized care plan and recommendations tailored to the patient's test results, including a summary and a list of in-depth actions for each evidence-based prevention strategy.
These recommendations can significantly differ depending on whether the result indicates low or high risk.
Explore these evidence-based strategies further in:
"Care Plan for Individuals at Risk of Preeclampsia: a Collaborative Approach to Education, Prevention Strategies, Surveillance, and Follow-Up" by J. Roberts et al. (AJOG 2023).
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Risks and warning signs
Whether your patient is at low or high risk, it is crucial that they comprehend the potential dangers of preeclampsia.
Both you and the patient need to stay alert for any signs and symptoms and promptly identify them if they do arise. This proactive approach enables swift action for the best possible care for both the mother and the baby.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
More information
In a clinical validation study, Encompass identified 9 out of 10 eligible pregnancies that developed preeclampsia between 20 and 37 weeks, months in advance. Note: clinical performance data is available upon request.
The performance characteristics of the Encompass test have been established in pregnant individuals age 35 or older and without a pre-existing major risk factor for preeclampsia, with a singleton pregnancy between 17 weeks 4 days and 22 weeks 0 days gestation.
Given this test is intended for screening preeclampsia risk, a "high-risk" result does not guarantee an affected pregnancy, and a "low-risk" result does not guarantee an unaffected pregnancy.
This is a mock test report. Your patient will receive one of two possible test results, either “low risk” or “high risk”. Explore each report by clicking the tabs.
Patient name: Jane Doe
Encompass result:
High Risk
There is an increased risk of developing preeclampsia in this pregnancy.
With a "high risk" result, Encompass Care Plus is recommended for your pregnancy. Remember, this result does not mean you will develop preeclampsia. In fact, with your recommended plan, you'll have tools to try to prevent it. Make sure to review it with your provider.
Patient name: Jane Doe
Medical history and risks
Jane, you reported no major risk factors for preeclampsia, but it's important to note that even individuals without major risk factors can still develop it. This is where your Encompass 'high-risk" result is helping you to know your objective risk for preeclampsia.
Patient name: Jane Doe
Your suggested care plan
Review the specific recommendations outlined in your "high-risk" care plan with your provider to determine the best plan for your pregnancy. This is a brief summary:
- Medications: Aspirin has been shown to be a safe and effective medication to lower your preeclampsia risk. Continue taking it if your doctor already recommended it or ask them if you should start it if you aren't.
- Monitoring and labs: High blood pressure is silent, but it is often the first sign of preeclampsia, so you must check it regularly. Your provider may also want to check your liver and kidney function and for protein in the urine.
- Nutrition: Healthy nutrition can have a big impact on your pregnancy and preeclampsia risk. The Mediterranean diet can lower preeclampsia risk. Vitamin D and calcium are also important.
- Exercise: Exercise can significantly lower your preeclampsia risk. It's best to combine aerobic and strength training.
- Sleep: Sleep is an important part of prevention. While it may seem simple, it can make a difference.
Patient name: Jane Doe
Understanding your risk
Preeclampsia can harm both moms and babies. For moms, it can lead to seizures, stroke, kidney and liver damage, and an increased risk of excessive blood loss during delivery. For babies, it can cause them to be smaller than normal and born prematurely. This might lead to a NICU stay or a longer stay in the hospital.
Preeclampsia can sometimes be silent, but there are certain symptoms to be aware of. Let your healthcare provider know if you experience any of the symptoms below. If your blood pressure is 140/90 or higher (for either number), contact your provider. If your blood pressure is 160/110 or higher (for either number), it could be an emergency, and you need immediate medical attention.
When there are symptoms, they may include:
- Headache that will not go away
- Shortness of breath
- Pain in the abdomen or shoulder
- Nausea or vomiting in the second half of pregnancy
- Seeing spots, blurry vision, changes in eyesight
- Swelling of face or hands
- Sudden weight gain
- High blood pressure
Patient name: Jane Doe
About the test
Encompass is a screening test, not a diagnostic. It evaluates gene expression levels in the maternal blood, which is a mixture of maternal, fetal and placental origin, to predict the chance for preeclampsia.
The test isolates RNA from the maternal blood, from which libraries are created and analyzed by next generation sequencing and analyzed using Mirvie’s proprietary bioinformatics pipeline.
Note: this is a mock test report. Clinical performance data is available upon request.
How your patients can order
Ordering the Encompass test before the 18-22 week window is a simple online and at-home process. Contact our team to learn more about availability in your area.
Encompass
test kit
blood draw
online
Landmark research
A landmark research effort has recently completed enrollment of a 10,000-person study. Led by internationally renowned experts in pregnancy health, this U.S.-based study aims to understand how RNA messages found in expectant mothers’ blood can predict life-threatening pregnancy complications. This study builds on breakthrough research published in Nature in 2022 to reveal the underlying biology of pregnancy health and predict preeclampsia risk months in advance.
Performance of Encompass
Using the Mirvie RNA platform, the 10,000-person study showed the Encompass test identified 9 out of 10 eligible pregnancies that developed preeclampsia between 20 and 37 weeks, months early. Eligible pregnancies are singleton, age 35 or older, and without a pre-existing major risk factor for preeclampsia.1
The test fills a crucial screening gap as the earlier preeclampsia strikes, the more severe its impacts are for mom and baby.
Clinical evidence
These results demonstrate the analytical and clinical validity of the Encompass test (available upon request.) The results are currently under review at a peer-reviewed journal. The test is now available via an Early Access Program from Mirvie’s CLIA-certified laboratory.
Preeclampsia prevention
Each test result will include an action plan for prevention based on the peer-reviewed evidence and materials that can be found on PreeclampsiaPrevention.com. Whether the results are low or high risk, there are many things you and your patient can work on together to lower their risk for preeclampsia even further. Each test report explains how to act on this information. Additionally, every test includes an SMS-based virtual assistant to help them simplify implementing their plan. They’ll get tips, guides, check-ins and reminders tailored to their action plan.
How it works
The test evaluates RNA expression patterns from the mom, baby, and placenta, which change dramatically as a pregnancy progresses. Instead of just one biomarker or a specific gene, the test evaluates the expression of a collection of genes that predicts the risk of preeclampsia in the pregnancy — all from a simple blood draw between 18-22 weeks.
About the test
The Encompass test is performed by a CLIA-certified lab to screen for preeclampsia risk.
The test is now available via an Early Access Program through Mirvie’s CLIA-certified laboratory.
Clinical performance data is available upon request.
Patients should always discuss their results and action plans with their care team.
Encompass is a screening test, not a diagnostic. It evaluates gene expression levels in the maternal blood, which is a mixture of maternal, fetal and placental origin, to predict the chance for preeclampsia.
The test isolates RNA from the maternal blood, from which libraries are created and analyzed by next generation sequencing and analyzed using Mirvie’s proprietary bioinformatics pipeline.
The performance characteristics of the Encompass test have been established in pregnant individuals age 35 or older and without a pre-existing major risk factor for preeclampsia, with a singleton pregnancy between 17 weeks 4 days and 22 weeks 0 days gestation.
References:
Rasmussen M, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature, 601:422-427 (2022)
Roberts J, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. Am J Obstet Gyn, 229(3):193-213 (2023)
Elovitz, et al. Mirvie validation data on file. Available upon request.
Connect with
our team.
Carrie Haverty, MS, CGC